CMS has announced that it will be reconsidering its 2013 decision to significantly limit Medicare coverage of amyloid beta proton emission tomography (PET) scans. This is an important opportunity to greatly expand access to this important diagnostic tool for people at risk of developing Alzheimer’s disease.

Between 2012 and 2020, more than 30 academic manuscripts involving more than 1,000 individual researchers have been published demonstrating how amyloid beta PET scans have empirically and repeatedly – even in the absence of critical disease-modifying therapeutics – demonstrated significant clinical utility by causing changed clinical management, changed patient diagnoses, and improved provider confidence.

PET scans are critical for patients at risk of developing Alzheimer’s Disease – the proof is in the data.

1,000+ individual researchers involved in studying the benefits of amyloid PET

31 published peer-reviewed papers demonstrating the benefits of amyloid PET

-- 31 studied clinical utility¹⁻³¹

5 studied appropriate use criteria (AUC)²⁻¹⁴,²⁻³²⁻⁻³⁴

More than 40 studies in over 15,000 patients have evaluated or utilized amyloid PET

-- 8 studied drugs in development²⁻¹⁴,²⁻³²⁻⁻³⁴

Knowing amyloid status adds clarity to the management of patients with suspected Alzheimer’s disease by helping to ensure:

- Fewer adverse events from inappropriate treatment
- Better chances for receiving appropriate care
- Reduced stress on caregivers

When combined with innovative new treatments, PET scans could help change the course of Alzheimer’s disease.

Today Alzheimer’s Disease is among the top 10 causes of death and the most feared disease in America.

Women and people of color are impacted disproportionately and often face additional barriers to healthcare access:

- Almost 2/3 of Americans with Alzheimer’s are women.
- Older Black Americans are about 2 times as likely as older Hispanics, 1.5 times as likely to have Alzheimer’s or other dementias as older Whites.

An accurate and timely diagnosis, and continued monitoring of, Alzheimer’s could help halt disease progression and save lives.

The potential impact PET scans could have on the Alzheimer’s community (and beyond) is immeasurable. We must encourage CMS to expand patient access to give hope to millions of Americans who could one day benefit.

Learn more at www.fightchronicdisease.org